Neoadjuvant T-VEC Efficacy Consistent at 5 Years for Resectable Melanoma
Source: Cancer Network, September 2022
Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.
Neoadjuvant treatment with the oncolytic virus T-VEC (talimogene laherparepvec; Imlygic) continued to demonstrate consistent improvements in efficacy at 5 years compared with surgery alone for patients with stage IIIB to IVM1a melanoma, according to long-term results from a phase 2 study (NCT02211131) presented at 2022 European Society for Medical Oncology Congress (ESMO).
At the final 5-year analysis of the open-label study, the 5-year relapse-free survival (RFS) rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone (HR, 0.76; 80% CI, 0.60-0.97). At 5 years, 77.3% of patients treated with T-VEC prior to surgery were alive compared with 62.7% with surgery alone (HR, 0.54; 80% CI, 0.36-0.81). The event-free survival (EFS) rate at 5 years was 43.7% with T-VEC vs 62.7% with surgery alone (HR, 0.57; 80% CI, 0.43-0.76).